Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Drugs in Development, 2021

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase Pim 3 – Drugs in Development, 2021, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) – Serine/threonine-protein kinase Pim-3 is an enzyme encoded by the PIM3. It prevents apoptosis. It contribute to tumorigenesis through the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), by regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Diffuse Large B-Cell Lymphoma, Hematological Tumor, Mantle Cell Lymphoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Non-Small Cell Lung Carcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)

– The report reviews Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Incyte Corp

Inflection Biosciences Ltd

NewBay Medical Technology Co Ltd

Novartis AG

Onconova Therapeutics Inc

Shengke Pharmaceuticals (Jiangsu) Ltd

Sumitomo Dainippon Pharma Oncology, Inc

X-37 LLC

Yakult Honsha Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Overview

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Companies Involved in Therapeutics Development

Incyte Corp

Inflection Biosciences Ltd

NewBay Medical Technology Co Ltd

Novartis AG

Onconova Therapeutics Inc

Shengke Pharmaceuticals (Jiangsu) Ltd

Sumitomo Dainippon Pharma Oncology, Inc

X-37 LLC

Yakult Honsha Co Ltd

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Drug Profiles

ETH-155008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBL-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-53914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LGB-321 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-108110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PIM1 and PIM3 for Hematological Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PIM3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-3654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Dormant Products

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Discontinued Products

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC

2.7.11.1) - Product Development Milestones

Featured News & Press Releases

May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020

Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis

May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors

Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer

Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology

Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Incyte Corp, 2021

Pipeline by Inflection Biosciences Ltd, 2021

Pipeline by NewBay Medical Technology Co Ltd, 2021

Pipeline by Novartis AG, 2021

Pipeline by Onconova Therapeutics Inc, 2021

Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2021

Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2021

Pipeline by X-37 LLC, 2021

Pipeline by Yakult Honsha Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports